» Articles » PMID: 36635052

Use-Dependent Relief of Inhibition of Nav1.8 Channels by A-887826

Overview
Journal Mol Pharmacol
Date 2023 Jan 12
PMID 36635052
Authors
Affiliations
Soon will be listed here.
Abstract

Sodium channel inhibitors used as local anesthetics, antiarrhythmics, or antiepileptics typically have the property of use-dependent inhibition, whereby inhibition is enhanced by repetitive channel activation. For targeting pain, Nav1.8 channels are an attractive target because they are prominent in primary pain-sensing neurons, with little or no expression in most other kinds of neurons, and a number of Nav1.8-targeted compounds have been developed. We examined the characteristics of Nav1.8 inhibition by one of the most potent Nav1.8 inhibitors so far described, A-887826, and found that when studied with physiologic resting potentials and physiologic temperatures, inhibition had strong "reverse use dependence", whereby inhibition was relieved by repetitive short depolarizations. This effect was much stronger with A-887826 than with A-803467, another Nav1.8 inhibitor. The use-dependent relief from inhibition was seen in both human Nav1.8 channels studied in a cell line and in native Nav1.8 channels in mouse dorsal root ganglion (DRG) neurons. In native Nav1.8 channels, substantial relief of inhibition occurred during repetitive stimulation by action potential waveforms at 5 Hz, suggesting that the phenomenon is likely important under physiologic conditions. SIGNIFICANCE STATEMENT: Nav1.8 sodium channels are expressed in primary pain-sensing neurons and are a prime current target for new drugs for pain. This work shows that one of the most potent Nav1.8 inhibitors, A-887826, has the unusual property that inhibition is relieved by repeated short depolarizations. This "reverse use dependence" may reduce inhibition during physiological firing and should be selected against in drug development.

Citing Articles

Discovery of E0199: A novel compound targeting both peripheral Na and K7 channels to alleviate neuropathic pain.

Zhang B, Shi X, Liu X, Liu Y, Li X, Wang Q J Pharm Anal. 2025; 15(1):101132.

PMID: 39906690 PMC: 11791318. DOI: 10.1016/j.jpha.2024.101132.


State-Dependent Inhibition of Nav1.8 Sodium Channels by VX-150 and VX-548.

Vaelli P, Fujita A, Jo S, Zhang H, Osorno T, Ma X Mol Pharmacol. 2024; 106(6):298-308.

PMID: 39322410 PMC: 11585256. DOI: 10.1124/molpharm.124.000944.


Frontiers in Acute Pain Management: Emerging Concepts in Pain Pathways and the Role of VX-548 as a Novel NaV1.8 Inhibitor: A Narrative Review.

Kaye A, Everett E, Lehuquet A, Mason J, Maitski R, Plessala M Curr Pain Headache Rep. 2024; 28(11):1135-1143.

PMID: 38963514 DOI: 10.1007/s11916-024-01295-7.

References
1.
Liu P, Blair N, Bean B . Action Potential Broadening in Capsaicin-Sensitive DRG Neurons from Frequency-Dependent Reduction of Kv3 Current. J Neurosci. 2017; 37(40):9705-9714. PMC: 5628410. DOI: 10.1523/JNEUROSCI.1703-17.2017. View

2.
Obeng S, Hiranita T, Leon F, McMahon L, McCurdy C . Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery. J Med Chem. 2021; 64(10):6523-6548. DOI: 10.1021/acs.jmedchem.1c00028. View

3.
Urru M, Muzzi M, Coppi E, Ranieri G, Buonvicino D, Camaioni E . Dexpramipexole blocks Nav1.8 sodium channels and provides analgesia in multiple nociceptive and neuropathic pain models. Pain. 2019; 161(4):831-841. DOI: 10.1097/j.pain.0000000000001774. View

4.
Bosmans F, Puopolo M, Martin-Eauclaire M, Bean B, Swartz K . Functional properties and toxin pharmacology of a dorsal root ganglion sodium channel viewed through its voltage sensors. J Gen Physiol. 2011; 138(1):59-72. PMC: 3135324. DOI: 10.1085/jgp.201110614. View

5.
Han C, Huang J, Waxman S . Sodium channel Nav1.8: Emerging links to human disease. Neurology. 2016; 86(5):473-83. DOI: 10.1212/WNL.0000000000002333. View